Le Lézard
Classified in: Health
Subjects: SVY, AVO

New Poll: 76% of Voters Concerned Speaker Pelosi's Plan Would Result in Fewer New Medicines


WASHINGTON, Dec. 5, 2019 /PRNewswire/ -- The House of Representatives has spent much of this fall focused on Speaker Pelosi's drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the right solution. In fact, voters have significant concerns and a large majority outright opposes it.

Survey respondents were presented with two approaches to addressing prescription medicine costs:

  1. Speaker Pelosi's plan which would allow the government to negotiate the price of 250 medicines plus insulins; rely on international reference pricing to determine a ceiling price for medicines; place a tax on pharmaceutical companies of up to 95% for not complying with the negotiation; implement an out-of-pocket cap on seniors' medicine costs; and penalize pharmaceutical companies for raising medicine prices above the rate of inflation.

  2. A more patient-focused plan that includes sharing the savings with patients at the pharmacy; increasing transparency for biopharmaceutical companies, hospitals and insurers; speeding approval of generic medicines; cracking down on gaming practices that interfere with competition; and implementing an annual cap on out-of-pocket costs for seniors.

When given a choice between the two approaches, only 28% prefer the proposed drug pricing legislation introduced by Speaker Pelosi.

The same holds true when you look specifically at voters in swing states (only 28% prefer Speaker Pelosi's plan) and Republicans (only 21% prefer Speaker Pelosi's plan). And among Democrats, only 35% of voters prefer Speaker Pelosi's plan. 

When presented with some of the consequences if Speaker Pelosi's plan were to be implemented, voters raised serious concerns.

While some members of Congress have argued that losing 8 to 15 new medicines over 10 years is a reasonable consequence to allow government to negotiate medicine prices and crack down on pharmaceutical companies, few find this argument particularly convincing with 50% saying it is unconvincing, only 9% saying it is very convincing and 28% saying it is somewhat convincing (13% are unsure). This is because most voters (76%) say they are concerned about losing 8 to 15 new medicines as a result of Speaker Pelosi's plan.

Imagine what voters would think about it if they learned several experts believe the Congressional Budget Office's estimate that Speaker Pelosi's plan would result in a loss of 8 to 15 new medicines over 10 years is a significant underestimate. One recent study shows that under her plan small, emerging biotech companies alone would bring 56 fewer innovative new medicines to market over the next 10 years. While the White House Council of Economic Advisers released an analysis that found Speaker Pelosi's bill "could lead to as many as 100 fewer drugs entering the United States market over the next decade, or about one-third of the total number of drugs expected to enter the market during that time."

Voters support the pragmatic approach to lowering medicine prices over Speaker Pelosi's plan, including sharing negotiated savings at the pharmacy, getting more generics to market and making seniors' medicine costs more affordable and predictable throughout the year.

Rather than pursing an aggressive approach that would upend our entire system, Congress should listen to voters and pursue targeted and practical solutions that will lower costs and protect future innovations.

Read the full survey results here.

This post originally appeared on PhRMA's Catalyst blog.

CONTACT: Nicole Longo, [email protected], 202-835-3460

SOURCE Pharmaceutical Research and Manufacturers of America (PhRMA)


These press releases may also interest you

at 08:30
Assure Holdings Corp. (the "Company" or "Assure") , a provider of intraoperative neuromonitoring ("IONM") and remote neurology services, today announced that it closed the sale of certain assets of its IONM business to MPOWERHealth on March 26, 2024....

at 08:30
SweetWater Brewing Company ("SweetWater Brewing" or "SweetWater"), the largest craft brewer in the Southeast and a subsidiary of Tilray Brands, Inc. , announced today the release of its new Hammer Red Amber Ale, the latest collaboration beer as part...

at 08:25
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell...

at 08:16
Canadian health care providers now have access to clinical tools and resources they need to better support older adults experiencing...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...



News published on and distributed by: